Applied Therapeutics, Inc. (APLT) Revenue History
Annual and quarterly revenue from 2017 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
APLT Revenue Growth
Revenue Breakdown (FY 2024)
APLT's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
APLT Revenue Analysis (2017–2024)
As of May 8, 2026, Applied Therapeutics, Inc. (APLT) generated trailing twelve-month (TTM) revenue of $1.0 million, reflecting explosive growth of +719.7% year-over-year. The most recent quarter (Q3 2025) recorded $1.0 million in revenue.
Looking at the longer-term picture, APLT's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $10.0 million in 2023.
Revenue diversification analysis shows APLT's business is primarily driven by Research and Development Services (100%). With over half of revenue concentrated in Research and Development Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RARE (+13.3% YoY), FOLD (+20.0% YoY), and ACAD (+9.9% YoY), APLT has outperformed the peer group in terms of revenue growth. Compare APLT vs RARE →
APLT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| APLTCurrent | $1M | +719.7% | - | -22922.9% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 KRYS | $389M | +25.1% | - | 41.5% |
APLT Historical Revenue Data (2017–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $455K | -95.4% | $-48,289,000 | -10613.0% | $-104,299,000 | -22922.9% |
| 2023 | $10.0M | - | $-43,912,000 | -439.4% | $-64,535,000 | -645.8% |
| 2022 | $0 | - | $-441,000 | - | $-82,950,000 | - |
| 2021 | $0 | - | $0 | - | $-105,618,000 | - |
| 2020 | $0 | - | $0 | - | $-94,466,000 | - |
| 2019 | $0 | - | $-23,000 | - | $-45,582,000 | - |
| 2018 | $0 | - | $0 | - | $-13,518,000 | - |
| 2017 | $0 | - | $0 | - | $-4,285,000 | - |
See APLT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs APLT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare APLT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAPLT — Frequently Asked Questions
Quick answers to the most common questions about buying APLT stock.
Is APLT's revenue growth accelerating or slowing?
APLT revenue is accelerating at +719.7% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $1M. Growth momentum has increased versus prior periods.
What is APLT's long-term revenue growth rate?
Applied Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +719.7% is above this long-term average.
How is APLT's revenue distributed by segment?
APLT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2024 are available for download. Segment mix reveals concentration and diversification trends.